Gemin X Pharmaceuticals
Develops and commercializes targeted cancer therapeutics to improve the lives of patients.
Launch date
Employees
Market cap
-
Enterprise valuation
€29—44m (Dealroom.co estimates Aug 2010.)
Malvern Iowa (HQ & founding location)
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | N/A | - |
N/A | N/A | Series A | |
$38.0m | Series C | ||
N/A | $9.3m | Debt | |
$16.0m | Series D | ||
$8.0m | Series E | ||
$225m | Acquisition | ||
Total Funding | €56.4m |
Related Content
Recent News about Gemin X Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.